N/A
Completed N=4,856
Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics
Source: ClinicalTrials.gov NCT02299791 ↗Enrolled (actual)
4,856
Serious AEs
—
Results posted
Oct 2017
Primary outcomePrimary: Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both — 1279; 1318 Participants
Summary
The purpose of the ALL Study is to determine the effectiveness of the dissemination of the ALL intervention from an integrated care setting into Community Health Centers (CHCs) by measuring changes in diabetes mellitus (DM) population prescription rates for the medications, using a pre-post comparison within clinics and a staggered, randomized implementation across clinics.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both |
1279; 1318 | — |
Eligibility Criteria
Inclusion Criteria
- Convenience sample of 11 community health clinics (CHCs) that are members of OCHIN, Inc.
Exclusion Criteria
- none, for study CHCs
Data sourced from ClinicalTrials.gov (NCT02299791). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.